Format

Send to

Choose Destination
Vaccine. 2012 Jun 22;30(30):4490-8. doi: 10.1016/j.vaccine.2012.04.069. Epub 2012 May 3.

A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models.

Author information

1
Department of Infectious, Parasitic and Immunomediated Diseases, ISS, Rome, Italy.

Abstract

A novel vaccine (PEV7) consisting of a truncated, recombinant aspartyl proteinase-2 of Candida albicans incorporated into influenza virosomes was studied. This vaccine candidate generated a potent serum antibody response in mouse and rat following intramuscular immunization. Anti-Sap2 IgG and IgA were also detected in the vaginal fluid of rats following intravaginal or intramuscular plus intravaginal administration. In a rat model of candidal vaginitis, PEV7 induced significant, long-lasting, likely antibody-mediated, protection following intravaginal route of immunization. PEV7 was also found to be safe in a repeated-dose toxicological study in rats. Overall, these data provide a sound basis to envisage the clinical development of this new candidate vaccine against candidal vaginitis.

PMID:
22561143
DOI:
10.1016/j.vaccine.2012.04.069
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center